HER2-targeted monoclonal antibody combination

This page covers all HER2-targeted monoclonal antibody combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HER2 (human epidermal growth factor receptor 2).

Targets

HER2 (human epidermal growth factor receptor 2)

Marketed (3)

• Pertuzumab and Trastuzumab · QuantumLeap Healthcare Collaborative · Oncology
  Pertuzumab and trastuzumab are monoclonal antibodies that block HER2 signaling in cancer cells by binding to different epitopes of the HER2 receptor, preventing tumor growth and survival.
• Trastuzumab + Pertuzumab · Massachusetts General Hospital · Oncology
  Trastuzumab and pertuzumab are monoclonal antibodies that block HER2 signaling by binding to different epitopes on the HER2 receptor, preventing tumor cell growth in HER2-positive cancers.
• Pertuzumab + trastuzumab · European Organisation for Research and Treatment of Cancer - EORTC · Oncology
  Pertuzumab and trastuzumab are monoclonal antibodies that block HER2 signaling by binding to different epitopes on the HER2 receptor, preventing ligand-induced dimerization and receptor activation.

Phase 3 pipeline (2)

• FDC of Pertuzumab and Trastuzumab SC · Hoffmann-La Roche · Oncology
  This fixed-dose combination of two monoclonal antibodies blocks HER2 signaling by targeting the HER2 receptor from different epitopes, preventing tumor cell growth and survival.
• Pertuzumab and Trastuzumab FDC SC · Hoffmann-La Roche · Oncology
  This fixed-dose combination of two monoclonal antibodies blocks HER2 signaling by targeting different epitopes on the HER2 receptor, preventing tumor cell growth and survival.

Patent intelligence

• her2 targeted monoclonal antibody combination patent landscape — aggregated cliff calendar, attackable patents, originator estates